| Metric | Q4'25 | Q1'26 | Change |
|---|---|---|---|
| Consolidated Revenue | $24.5B (Q4) | $21.2B (Q1) | Seasonal decline but beat internal plan |
| Consolidated Operating Margin | 11.8% (Q4) | 6.2% (Q1) | 540 bps decline, 250 bps from transitory costs |
| US Domestic Revenue | $16.8B (Q4) | $14.1B (Q1) | Down 2.3% YoY vs 8% volume decline |
| US Domestic Operating Margin | 10.2% (Q4) | 4.0% (Q1) | 620 bps decline, 250 bps transitory |
| Revenue Per Piece (US) | 8.3% growth (Q4) | 6.5% growth (Q1) | 170 bps deceleration but still robust |
| International Revenue | $5.0B (Q4) | $4.5B (Q1) | Up 3.8% YoY, beat expectations significantly |
| International Operating Margin | 18.0% (Q4) | 12.1% (Q1) | 590 bps decline from trade disruption |
| SMB Penetration (US) | 31.2% (Q4) | 34.5% (Q1) | 330 bps improvement, highest in history |
| B2B Penetration (US) | 37.5% (Q4) | 45.2% (Q1) | 770 bps improvement, highest Q1 in 6 years |
| Healthcare Revenue | Not disclosed | $3B+ (Q1) | First $3B+ healthcare quarter ever |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.